Sunshine Biopharma Inc.

Snapshot

Sunshine Biopharma is a tiny generic-drug and oncology-research company with $36.3M in FY 2025 revenue, up 4.1% YoY, and a 32.8% gross margin, but it lost $6.0M for the year and burned $5.5M in free cash flow.

What's Happening Right Now

• Fri 2nd Oct '26 · Offering: Sunshine Biopharma filed an S-1 for a $7.0M offering plus new warrants, which would take shares outstanding from 4.3M to over 14.5M, with tens of millions more shares possible from existing warrants.
• Fri 2nd Oct '26 · ATM sale: Sold $2.23M net / 1.86M shares through its at-the-market program, as stated for Jul 27, 2026 to Oct 2, 2026.
• Fri 2nd Oct '26 · Registration: Registered 10.18M shares for sale on Form S-1.
• Mon 28th Sep '26 · Reverse split: CEO Steve Slilaty, who holds about 97% of voting power, approved a second reverse split (up to 1-for-20) within a year to try to fix Nasdaq's minimum bid-price compliance.
• Thu 24th Sep '26 · Product launch: Sunshine Biopharma launched generic ondansetron (Zofran equivalent) tablets in Canada through its Nora Pharma distribution network, adding to its generic drug portfolio.
• Wed 9th Sep '26 · Warrant overhang: A new prospectus registers 25.5M shares tied to Series B Warrants with a downward-resetting strike price, alongside disclosure of three reverse splits since April 2024 and ongoing delisting exposure.
• Tue 8th Sep '26 · Registration: Registered 25.48M shares for sale on Form S-1.
• Sun 12th Jul '26 · Settlement: The company agreed to pay about US$1.06 million to settle a dispute with Nora Pharma's former president over a 2022 acquisition and termination claims.